We have located links that may give you full text access.
Paratesticular rhabdomyosarcoma in childhood.
Journal of Urology 1977 September
Ten boys with paratesticular embryonal rhabdomyosarcoma were treated in a 44-year period. Two prognostically distinct stages of the disease and appropriate treatments are described. Children with non-infiltrating tumors (stage IA) are curable (3 patients are alive and free of tumor after 8 to 44 years) and radical orchiectomy with adjunctive radiation or, preferably, chemotherapy is adequate for these patients. Conversely, in those children with infiltrative tumors retroperitoneal nodal metastases invariably develop. Early retroperitoneal lymphadenectomy with adjuvant radiation and multidrug cyclic chemotherapy is life-saving (3 are alive and free of tumor after 2 1/2 to 4 years). However, delayed recognition and treatment of retroperitoneal disease, despite agressive therapy, is frequently disappointing--2 of 4 patients died after 2 and 6 years; another, who had advanced disease, is lost to followup and also is presumed dead and 1 is alive and free of tumor after 6 1/2 years.
Full text links
Related Resources
Trending Papers
Obesity pharmacotherapy in older adults: a narrative review of evidence.International Journal of Obesity 2024 May 7
Haemodynamic monitoring during noncardiac surgery: past, present, and future.Journal of Clinical Monitoring and Computing 2024 April 31
SGLT2 Inhibitors in Kidney Diseases-A Narrative Review.International Journal of Molecular Sciences 2024 May 2
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app